Drugs / GSK3186899
GSK3186899
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03874234 | Apr → Oct 2019 | leishmaniasis | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3186899 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03874234 ↗ |
| Known as | DDD-853651 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4563818 ↗ |
| Known as | GSK3186899A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4563818 ↗ |
| Modality | Small molecule | — CHEMBL4563818 ↗ |
| Route | Oral | “to be administered orally” NCT03874234 ↗ |